Fabrazyme

Agalsidase β

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Fabry disease. Reduces globotriaosylceramide (GL-3) deposition in kidney capillary endothelium & certain other cell types.

IV 1 mg/kg infusion every 2 wk. Max initial infusion rate: 0.25 mg/min (15 mg/hr). If tolerated, infusion may be increased in increments of 0.05-0.08 mg/min (3-5 mg/hr) w/ each subsequent infusion. Patient weighing ≥30 kg Min infusion duration: 1.5 hr, <30 kg Max infusion rate: 0.25 mg/min (15 mg/hr). Patient w/ +ve skin test to Fabrazyme or tested +ve for anti-Fabrazyme IgE Initial rechallenge: Low dose at lower infusion rate [eg, ½ the therapeutic dose (0.5 mg/kg) at infusion rate 0.01 mg/min]. As tolerated, may be increased to 1 mg/kg & slowly increase infusion by titrating upwards (doubled every 30 min up to max rate of 0.25 mg/min).

Other Agents Affecting Metabolism

A16AB04 - agalsidase beta ; Belongs to the class of enzymes. Used in the treatment of alimentary tract and metabolism problems.

POM